Pacira Biosciences invested $3 million in Spine BioPharma.
The investment was in the form of a convertible note, according to an April 20 news release. It will support the development of Remedisc, a therapeutic for the treatment of degenerative disc disease.
Pacira plans to make an additional $7 million investment based on future milestones. The investment follows Spine BioPharma's recent series A financing round.
More articles on biologics:
Florida surgeon performs disc replacement on wrong area of patient's spine
2 spine surgeon leaders exit Johns Hopkins
5 high-profile device company court battles: Medtronic, Smith+Nephew & more